Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mesenchymal Stromal Cell Clear all
Active, not recruiting Phase 2 Interventional Results available

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

NCT03268603
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Autologous Adipose-derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 3, 2026, 8:15 PM EDT
Terminated Phase 1 Interventional

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

NCT03840343
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions
Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Early Phase 1 Interventional

Intra-Osseous Co-Transplant of UCB and hMSC

NCT02181478
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Myelofibrosis, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Lymphoid Malignancies, Chronic Myelogenous Leukemia
Interventions
cyclophosphamide, fludarabine phosphate, total-body irradiation, cyclosporine, mycophenolate mofetil, umbilical cord blood transplantation, mesenchymal stem cell transplantation
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients

NCT05456243
View directory record Official record
Conditions
Kidney Transplant
Interventions
Low dose adipose tissue derived mesenchymal stromal cells (A-MSC), High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Early Phase 1 Interventional

Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

NCT04723303
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
Umbilical Cord Lining Stem Cells
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

NCT00957931
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Bone marrow transplantation, Mesenchymal Stromal Cells
Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 3, 2026, 8:15 PM EDT
Not listed Phase 1 Interventional

Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis

NCT04043819
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PSC-01
Drug
Lead sponsor
Personalized Stem Cells, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Carlsbad, California • La Mesa, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 3, 2026, 8:15 PM EDT
Withdrawn Phase 1 Interventional

Phase 1 Crohn's Pediatric Sub-study of MSC AFP

NCT03014219
View directory record Official record
Conditions
Perianal Fistula
Interventions
Only 1 arm: treatment with MSC-AFP
Drug
Lead sponsor
William A. Faubion, M.D.
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease

NCT02150551
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Allogeneic bone marrow-derived mesenchymal stromal cells
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
12 Years to 22 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 3, 2026, 8:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids

NCT02379442
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
MSC
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 3, 2026, 8:15 PM EDT
Suspended Phase 2 Interventional

Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease

NCT03325322
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Fisetin, Placebo oral capsule
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 3, 2026, 8:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

NCT03608631
View directory record Official record
Conditions
KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

NCT04345601
View directory record Official record
Conditions
Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Mesenchymal Stromal Cells, Supportive Care
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta

NCT01061099
View directory record Official record
Conditions
Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III
Interventions
Mesenchymal Stromal Cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

NCT03473301
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Infusion of allogeneic umbilical cord blood, Infusion of MSCs
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
24 Months to 60 Months
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 3, 2026, 8:15 PM EDT
Active, not recruiting Phase 3 Interventional

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

NCT06489028
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
allo-APZ2-CVU, Placebo
Drug
Lead sponsor
RHEACELL GmbH & Co. KG
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Hialeah, Florida • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

NCT00951210
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
40 Years to 81 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Birmingham, Alabama • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 3, 2026, 8:15 PM EDT
Active, not recruiting Phase 1 Interventional

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

NCT05820711
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
MSC
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

BMT Autologous MSCs for GvHD

NCT02359929
View directory record Official record
Conditions
Graft Versus Host Disease, Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease
Interventions
Autologous mesenchymal stromal cells (MSCs)
Biological
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)

NCT02589119
View directory record Official record
Conditions
Perianal Fistula, Cryptoglandular Perianal Fistula
Interventions
MSC-AFP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis

NCT02805855
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Autologous Adipose-Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Jacob L. Sellon, M.D.
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

hCT-MSC Infusion in Adults With Autism Spectrum Disorder

NCT04484077
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism
Interventions
hCT-MSC
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 34 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 3, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cell and Islet Co-transplantation

NCT02384018
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes
Interventions
autologous mesenchymal stromal cell
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 69 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 3, 2026, 8:15 PM EDT